


332


333 **Supplementary Figure 1.** Although the cortical CS1P1 SUVRs using the cerebellum-cortex
334 have high test-retest reliability, there is poor discriminability between subjects, with all SUVRs
335 hovering around 1. Many SUVRs are less than one, indicating the cerebellum-cortex has more
336 uptake than the cortex and is not a preferred reference region for this tracer.

337



338

339 **Supplementary Figure 2. Pathway-specific correlations and causal mediation of the S1PR1**
 340 **neuroimmune cascade.** (A) Pairwise scatter plots illustrating the age, sex, and A β 42/40 adjusted
 341 relationships between sequential nodes of the modeled SEM cascade (Peripheral CD40LG →
 342 BBB Integrity → CS1P1 SUVR → GFAP). (B) Stacked bar chart quantifying the formal causal
 343 mediation analysis. The specific S1PR1-mediated endothelial cascade accounts for 25.5% of the
 344 total inflammatory drive from peripheral CD40LG to central GFAP. (C) Hierarchically clustered
 345 Spearman correlation heatmap of the upregulated inflammatory proteins and [11C]-CS1P1
 346 SUVR. Color intensity reflects the strength and direction of significant correlations ($p < 0.05$);
 347 non-significant correlations are left blank.




348

349 **Supplementary Figure 3: Re-evaluation of the S1PR1 neuroimmune cascade excluding**
 350 **plasma A β 42/40 as a covariate.** (A) Linear regression demonstrating a significant positive
 351 association between adjusted cortical [11 C]CS1P1 SUVR and plasma GFAP ($\beta = 0.157 \pm 0.052, p$
 352 $= 0.005$), controlling only for age and sex. (B) Volcano plot of the differential abundance analysis
 353 evaluating inflammatory plasma proteins against cortical [11 C]CS1P1 SUVR. Removing
 354 A β 42/40 as a covariate introduces additional significant peripheral and central markers (e.g.,
 355 TAF A5, CX3CL1, CCL2) into the uncorrected significance threshold. (C) Structural Equation
 356 Modeling (SEM) path diagram isolating the astrocytic signaling cascade without adjusting for

357 baseline amyloid pathology. Failure to account for the inflammatory variance driven by A β 42/40
358 suppresses the S1PR1 signal, rendering the specific pathway from blood-brain barrier (BBB)
359 disruption to central S1PR1 upregulation statistically insignificant ($\beta = 0.287$, $p = 0.072$). This
360 indicates that adjusting for baseline AD pathology is required to isolate the independent
361 peripheral-to-central neurovascular pathway.

362



363

364 **Supplementary Figure 4: Sensitivity analysis of the S1PR1 neuroimmune cascade utilizing**
 365 **plasma ptau-217 as a covariate.** To ensure the structural model was not dependent on the
 366 specific Alzheimer's pathology biomarker utilized, analyses were re-evaluated using NULISaseq
 367 plasma brain derived ptau-217 in place of the A β 42/40 ratio. (A) Linear regression demonstrates
 368 the positive association between adjusted cortical [11 C]CS1P1 SUVR and plasma GFAP remains
 369 significant ($\beta = 0.175 \pm 0.056, p = 0.003$). (B) Volcano plot of the differential abundance analysis
 370 confirming that the peripheral immune, endothelial, and central glial markers remain

371 significantly associated with [¹¹C]CS1P1 SUVR. (C) Structural Equation Modeling (SEM) path
372 diagram. The primary sequential cascade remains significant. Notably, while ptau-217
373 significantly independently predicts reactive astrogliosis (GFAP; $\beta = 0.236$, $p = 0.016$), it does
374 not predict S1PR1. (D) Mediation analysis estimates the S1PR1 pathway accounts for 31.8% of
375 the total inflammatory drive from peripheral CD40LG to central GFAP under these covariate
376 parameters.

377

378

379

380

*Supplementary Table 1: Intraclass Correlation
Coefficients (ICC) by Reference Region*

Reference Region	Cortical SUVR ICC	95% CI	p-value
Cerebellum- Cortex	0.802	[0.010, 0.990]	0.038
Corpus Callosum	0.735	[-0.640, 0.980]	0.101
Brainstem	0.669	[-0.240, 0.970]	0.094
Whole Cerebellum	0.535	[-0.290, 0.960]	0.138
Cerebellum White Matter	0.239	[-0.480, 0.910]	0.319

Supplementary Table 2: Full Parameter Estimates for the S1PR1 Mediation Model

Structural Path / Parameter	Unstandardized Estimate	Standard Error	Z-Value	P-Value	Standardized β
BBB \rightarrow ICAM1 (Factor Loading)	0.365	0.060	6.119	< 0.001	0.915
BBB \rightarrow TEK (Factor Loading)	0.304	0.052	5.888	< 0.001	0.827
CD40LG \rightarrow BBB	1.186	0.328	3.610	< 0.001	0.563
BBB \rightarrow CS1P1 CTX SUVR	0.076	0.028	2.699	0.007	0.406
CS1P1 CTX SUVR \rightarrow GFAP	0.815	0.406	2.006	0.045	0.196
CD40LG \rightarrow GFAP	0.213	0.147	1.451	0.147	0.131
Age \rightarrow BBB	0.007	0.011	0.673	0.501	0.105
Sex \rightarrow BBB	1.175	0.507	2.316	0.021	0.341
A β 42/40 \rightarrow BBB	1.414	4.947	0.286	0.775	0.045
Age \rightarrow CS1P1 CTX SUVR	-0.001	0.002	-0.484	0.629	-0.074
Sex \rightarrow CS1P1 CTX SUVR	-0.158	0.090	-1.755	0.079	-0.246
A β 42/40 \rightarrow CS1P1 CTX SUVR	-2.467	0.896	-2.753	0.006	-0.426
Age \rightarrow GFAP	0.033	0.005	6.163	< 0.001	0.626
Sex \rightarrow GFAP	-0.263	0.243	-1.084	0.278	-0.099
A β 42/40 \rightarrow GFAP	-3.766	2.668	-1.412	0.158	-0.157
Indirect (Defined Effect)	0.073	0.048	1.528	0.127	0.045
Total (Defined Effect)	0.286	0.146	1.964	0.050	0.176
Proportion mediated (Defined Effect)	0.255	0.197	1.296	0.195	0.255

Supplementary Table 3: Structural Equation Model Configurations and Fit Comparisons

Model	χ^2	df	Model p-value	CFI	RMSEA	AIC	BIC
Ideal Fit Thresholds	-	-	> 0.05	≥ 0.95	< 0.08	Lower is better*	Lower is better*
1A. Primary Sequence: CD40LG → BBB → S1PR1 → GFAP	3.127	7	0.873	1.000	0.000	158.40	191.41
1B. Alt Sequence: CD40LG → BBB → GFAP → S1PR1	5.129	7	0.644	1.000	0.000	160.40	193.41
1C. Alt Sequence (Reverse): GFAP → S1PR1 → BBB → CD40LG	4.062	7	0.773	1.000	0.000	158.27	191.29
1D. Alt Sequence: CD40LG → S1PR1 → BBB → GFAP	15.201	7	0.034	0.917	0.167	170.47	203.49
2A. Microglial Outcome: GFAP swapped for TREM1	17.735	7	0.013	0.879	0.191	140.45	173.46
2B. Dual Outcome: Separate (GFAP + TREM1)	18.143	9	0.034	0.930	0.156	224.41	269.59
2C. Dual Outcome: Latent CNS (GFAP + TREM1)	23.332	13	0.038	0.920	0.138	221.60	259.83

*Note: AIC and BIC are relative parsimony indices. They can be directly compared within Group 1 (1A, 1B, 1C, 1D) because the models evaluate identical variables. Models evaluating alternative causal directions (1D) or microglial activation (2A, 2B, 2C) universally fail absolute fit criteria (CFI < 0.95, RMSEA > 0.08, red), confirming both the specific directionality and astrocytic specificity of the cascade.